Which Dax shares do you have in your portfolio?
Source: https://t.co/1KCO9l8ZsE
#dax
#dividend
#dividende
#dividends
$ADS (-0,23%)
$AIR (-8,31%)
$ALV (-8,43%)
$BAS (-5%)
$BAYN (-6,12%)
$BMW (-5,51%)
$BEI (-0,89%)
Postos
215Which Dax shares do you have in your portfolio?
Source: https://t.co/1KCO9l8ZsE
#dax
#dividend
#dividende
#dividends
$ADS (-0,23%)
$AIR (-8,31%)
$ALV (-8,43%)
$BAS (-5%)
$BAYN (-6,12%)
$BMW (-5,51%)
$BEI (-0,89%)
In this article, I would like to give my personal assessment and opinion of some established pharmaceutical companies.
As a naive and uninformed person, I always believed that the pharmaceutical sector would play a major role in the future.
Now I have taken a closer look at the companies on the basis of fundamental key figures and have come to a very sobering conclusion.
However, I only evaluate the past and draw conclusions for the future from the past. I cannot evaluate and assess something like a pipeline because I lack the understanding and specialist knowledge.
-----------------------------------------------------------------------------------------------------------
I looked at the following companies:
Bayer $BAYN (-6,12%)
Eli Lilly $LLY (-7,56%)
Johnson & Johnson $JNJ (-3,01%)
Novo Nordisk $NOVO B (-6,66%)
Roche $ROG (-5,6%)
Pfizer $PFE (-4,59%)
Merck $MRK (-4,87%)
-----------------------------------------------------------------------------------------------------------
Let's start with the most popular title:
Novo Nordisk has the best fundamentals of all the stocks we looked at. The growth is right, the margins have been consistently above 30% since 2013 (unique selling point) and the return on equity is very high.
However, there has been disproportionately strong sales growth in the last 3 years. Probably due to GLP-1?
The question here is whether this growth can be maintained and whether sales can remain at this level? These uncertainties, as well as the regularization of GLP-1, could partly explain the fall in the share price in recent months. The valuation ratios are still quite sporty, but could this be justified in view of growth and margins? The quarterly figures will be very interesting.
I will start a savings plan and continue to monitor the shares.
-----------------------------------------------------------------------------------------------------------
Bayer AG has lost over 60% of its share price since the beginning of 2023. In my naivety, I thought that the share was now attractively valued. In fact, it has a price/sales ratio of just 0.47% and yet I would not invest.
If you look at the balance sheets of the last 10 years and further back, growth and profitability, you can see that the share has always been fundamentally weak. At best, it may be interesting for a trade, but I would not invest.
---------------------------------------------------------------------------------------------------------
Eli Lilly is basically a good company with solid figures. However, there have been one or two ups and downs over the years and balance sheets. If the company had invested in 2017 despite the poor figures at the time, it would be up several hundred percent today.
2024 was a record year for Eli Lilly with a 32 % increase in sales to around USD 45 billion. The main reason for this growth was the strong sales figures for diabetes drugs and weight loss injections.
In my opinion, the share is heavily overvalued despite its qualities and lags behind Novo Nordisk in many respects (fundamentally). I expect a significant correction here. This may not occur until 2026 or 27, but a price/earnings ratio of over 70 is in no way justified.
-----------------------------------------------------------------------------------------------------------
I think Johnson & Johnson is a conglomerate, as it also sells consumer goods. It has little to no growth, quite good profitability and a dividend of over 3%🤑.
I guess you don't necessarily have to own this share, as it doesn't stand out from the others in any way (but it does, it beats Bayer, for example, across the board) but it could possibly be a defensive stock for stability, if you value that sort of thing, and the dividend could also be a decisive factor if you buy it at the right time.
-----------------------------------------------------------------------------------------------------------
Pfizer is clearly a corona profiteer that achieved record sales in 2021 and 22. After Corona, the awakening and a share price drop of over 50 %.
From 2010-2020, sales even declined and margins ranged from 12% to over 40%. I suspect that the turn around to the pre-corona level could succeed, so my price target is $29-44.
Here, too, I do not see a quality company, not a must-have and at best a trade or the dividend, which is currently over 6%, could also be interesting here.
-----------------------------------------------------------------------------------------------------------
I thought only gold and chocolate came from Switzerland. That's not the case, because there is also Roche, not Ferrero Rocher but the pharmaceutical company. You would have to read up on this and find out more, because there seem to have been serious capital measures since 2022, which make the fundamental data look very negative.
So it looks (if the data from my data provider is correct) that Roche has not been profitable since 22. Operating profit in 2024 has fallen to a level similar to the lows of 2015 and 17. Cash flow and return on capital are negative and there has actually been no sales growth since 2019.
If you look at the company from 2011-2021, they were actually quite solidly positioned.
I don't want to make a clear judgment on Roche because I don't think I have enough information to be able to correctly interpret these figures for the last three years, because what looks like a pile of 💩 (chocolate) could also be an opportunity. But I don't know.
Incidentally, it looks very similar at Novartis $NOVN (-5,35%) looks very similar and so I am encouraged that there may be a political geographic background that needs to be identified in order to value these stocks correctly.
-----------------------------------------------------------------------------------------------------------
Merck shares are in the midfield. From 2010-2018, the figures even declined. Continuous growth has been observed since 2018, with record sales in the last 3 years in particular.
The share appears to be relatively cheaply valued with a P/E ratio of less than 14.
For me, the question remains whether this profitability is sustainable and whether a strong year will not be followed by another weak one. Personally, the risk/return ratio for Merck would be too low for me.
-----------------------------------------------------------------------------------------------------------
My conclusion:
I will keep my distance from the pharmaceutical sector, as I am not in a position to assess a pipeline and there could always be medical breakthroughs that I am unable to predict.
On the other hand, expected successes can also fail to materialize or lead to failures and economic losses due to official regulations.
In addition, research is very time and capital intensive and there is no guarantee of success.
I will be satisfied with the share of the pharmaceutical sector in my broadly diversified ETF and, contrary to the above conclusion, start a savings plan on Novo Nordisk 🤓
-----------------------------------------------------------------------------------------------------------
Thanks for reading and I welcome additions, corrections and opinions, but please don't be so hard on me. 😇
US tariff threats send Hong Kong stock market plummeting + Novo Nordisk secures rights to weight loss and diabetes drugs + Hornbach defies weak consumer sentiment and increases earnings + Bayer is recommended to stop glyphosate sales in the USA + Heidelberg Materials wants to pay more dividends
US tariff threats send Hong Kong stock market plummeting
Novo Nordisk $NOVO B (-6,66%)secures rights to weight and diabetes medication
Hornbach $HBH (-3,78%)defies weak consumer sentiment and posts surprisingly strong earnings growth
For will Bayer $BAYN (-6,12%)recommended a halt to glyphosate sales in the USA
Heidelberg Materials $HEI (-6,75%)wants to pay more dividends
Tuesday: Stock market dates, economic data, quarterly figures
06:00 EU: Acea, new car registrations, February
08:00 DE: Construction industry, new orders and sales January | Residential real estate prices (house price index) 4Q
10:00 DE: NordLB Norddeutsche Landesbank Girozentrale, annual results
10:00 DE: Ifo Business Climate Index PROGNOSE: 86.6 PREVIOUS: 85.2 Situation assessment PROGNOSE: 85.5 PREVIOUS: 85.0 Business expectations PROGNOSE: 88.0 PREVIOUS: 85.4
11:00 DE: Bundestag, Constituent Session, Berlin
11:30 EU: ECB, allotment of 7-day main refi tender
14:00 HU: Hungary's central bank PROGNOSE: n.a. previous: 6.50%
14:40 US: Fed Governor Kugler, speech on "Economic Landscape and Entrepreneurship"
15:00 BE: Business Climate Index March PROGNOSIS: n.a. previous: -12.3
15:00 US: Consumer Confidence Index March PROGNOSIS: 93.5 previous: 98.3
15:00 US: New Home Sales February FORECAST: +3.0% yoy previous: -10.5% yoy
As a listener to Bayer's conference call ($BAYN (-6,12%) ) on the results for the fourth quarter and the full year 2024, I was able to gain a deep insight into the company's current situation and future plans.
William Anderson, Bayer's CEO, began with a summary of the 2024 results and gave an outlook for 2025. Despite the challenges, he was optimistic about the company's long-term prospects. It was particularly emphasized that the results were in line with the forecasts adjusted in November and that the debt was reduced to 32.6 billion euros. could be reduced.
Wolfgang Nickl, Chief Financial Officer, provided more detailed information on the Group's financial performance. Sales rose slightly by 1%, while EBITDA pre exceptionals fell by 14% to EUR 10.1 billion. This decline was mainly due to lower results in the Crop Science Division and negative currency effects. For 2025, Bayer expects sales of between 45 and 47 billion euros and EBITDA of between 9.5 and 10 billion euros. Free cash flow is expected to be between EUR 1.5 and 2.5 billion and net financial debt is expected to fall to between EUR 31 and 32 billion.
Anderson emphasized that Bayer will focus on reducing debton reducing debt, overcoming legal disputes and increasing profitability. An important point is the improving profitability in Crop Sciencewhere generic price pressure and regulatory challenges are putting pressure on margins. Bayer plans to accelerate growth through innovation and efficiency improvements and increase margins to mid-20% by 2029.
Pharmaceuticals: Stefan Oelrich, Head of the Pharmaceuticals Division, reported sales growth of 3.3% in 2024, driven by the strong performance of the new drugs Nubeqa and Kerendia. However, a decline in sales is expected for 2025, as the patent expiry of Xarelto will have a negative impact on earnings. Bayer plans to return to growth from 2027 through new product launches and an improved pipeline.
Consumer Health: Julio Triana, Head of the Consumer Health Division, highlighted growth in almost all categories, particularly in dermatology and digestive health. Further sales growth of between 2% and 5% is expected for 2025.
Crop Science: Rodrigo Santos, Head of the Crop Science Division, described 2024 as challenging, with a 2% decline in sales. Lower prices for glyphosate and regulatory hurdles had a negative impact on results. A slow market recovery is expected in 2025, and Bayer plans to increase profitability and growth through a comprehensive five-year strategy.
The subsequent Q&A session provided further insight into Bayer's strategic thinking. Here are some of the key points:
Asundexian: An analyst asked about the potential of Asundexian, a stroke prevention drug. Oelrich confirmed that the results of the Phase III trial are expected in the second half of the year and that the drug has blockbuster potential if the outcome is positive.
Dicamba: Another focus was on the regulatory challenges surrounding dicamba, an herbicide. Santos explained that Bayer is working on a solution for the next season and is confident that a new herbicide will be approved for 2026.
Glyphosate: Analysts were also interested in the impact of tariffs on glyphosate imports. Santos mentioned that tariffs on imports from China could potentially have a positive impact on prices.
Short-Stature Corn: Steve Byrne of Bank of America asked about the results of short-stem corn trials. Santos responded that the data to date shows higher yields at high density and no increased problems with weeds or disease have been noted.
Litigation: William Anderson outlined Bayer's strategy to address ongoing litigation related to PCBs and glyphosate. He emphasized that Bayer is committed to a scientific discussion of the facts.
Pipeline: Analysts expressed their interest in the pipeline and when initial results can be expected. Oelrich indicated that a more detailed update will be given later this year.
Profitability: The surprise inclusion of Crop Science profitability as a fifth focus area was questioned by analysts. Anderson explained that this was due to the structural problems in Crop Protection.
The conference call provided a comprehensive picture of Bayer in a period of upheaval. The company is facing significant challenges, particularly in connection with the patent expiry of Xarelto and the legal disputes in Crop Science. At the same time, however, there are also promising opportunities for growth, particularly through new product launches and an improved pipeline. Bayer's strategic priorities of reducing debt, managing litigation and increasing profitability appear well placed to position the company for long-term success.
Do any of you have Bayer in your portfolio?
Bayer $BAYN (-6,12%) is considering a possible ban on the sale of glyphosate in the USA. Since the takeover of glyphosate developer Monsanto a few years ago, the company has had to contend with a wave of lawsuits that have cost it billions. Analysts at Jefferies report that Bayer is facing the decision to stop selling the controversial herbicide if there is no clear regulatory perspective. Since 2018, Bayer has been facing major challenges in the glyphosate business as the number of lawsuits has risen to around 181,000. In order to prepare for possible financial burdens, the Group has set aside provisions of 5.9 billion dollars. Sales of glyphosate products are forecast to fall by 7.5 percent to 2.6 billion euros in 2024. An exit from this business segment has not yet been officially addressed, but a realignment is being considered. The situation remains tense and it remains to be seen how Bayer will respond to the challenges.
In the USA, industry is surprisingly weaker than expected, although it has recently returned to growth. The Purchasing Managers' Index, an important indicator of economic health, fell from 50.9 to 50.3 points, below economists' expectations. Although this mark remains above the growth threshold, the slowdown is clearly noticeable. Costs for industrial companies have reached their highest level since summer 2022, highlighting the challenges in this sector. Experts assume that the US Federal Reserve will not be forced to ease monetary policy more quickly under these conditions, as the risks to price trends are on the upside. In addition, construction spending fell by 0.2% in January, further underlining the difficulties in the construction industry. The economic situation therefore remains tense and could prove challenging in the coming months.
Sources:
As every Sunday, the most important news from the past week, as well as the most important dates for the coming week.
Also as a video:
https://youtube.com/shorts/jsEEQ7p900o?si=YxUmTubdAPwHFSPq
Sunday:
Trump announces a strategic crypto reserve, the price of Bitcoin rises again. In addition to Bitcoin and Ether, investments are also to be made in Cardano, Solana and Ripple. 'The USA is to become the crypto capital of the world'
https://www.n-tv.de/wirtschaft/Trump-kuendigt-strategische-Krypto-Reserve-an-article25599761.html
Monday:
The EU Commission wants to relax the climate targets. The shares of the car manufacturers, $VOW3 (-4,37%) VW, $BMW (-5,51%) BMW and $MBG (-5,9%) Mercedes can rise significantly. The annual targets are to be combined into a compensation period. This would give the car manufacturers more time in case of doubt.
Inflation is falling slightly less than expected. In February, inflation in the eurozone was 2.4%. The expected figure was 2.3%, compared with 2.5% in January. The next interest rate cut is expected on Thursday.
Wednesday:
Sales at$BAYN (-6,12%) Bayer stagnated in 2024, EBITDA fell by 22%. However, things are expected to pick up again in 2026. The bottom line was a loss of 2.55 billion euros. Shareholders will receive a dividend of 0.11 euros per share. Bayer had already cut the dividend to the minimum last year in order to reduce debt. A dividend is to be paid again from 2027. On Friday, it was announced that the company plans to seek approval for the possibility of a capital increase at the AGM.
The economic data from the USA is better than expected. The purchasing managers' index in particular is above expectations. However, there is much to suggest that prices will continue to rise. The order situation and employment are also improving compared to the previous month.
https://finanzmarktwelt.de/usa-ism-index-service-2-341270/
Thursday:
$DHLGY (-7,27%) DHL cuts 8,000 jobs in the mail and parcel business after poor figures. Earnings per share fell from 3.09 to 2.86 euros. The dividend is to be kept stable at 1.85 euros per share. The revenue forecast, which was lowered in the fall, was exceeded.
Thursday:
No big surprise: the ECB cuts the key interest rate for the 6th time to 2.5%. However, the debate about further interest rate cuts becomes more heated. A pause in interest rates is likely to come at the latest at an interest rate of 1.75%.
https://www.n-tv.de/wirtschaft/EZB-senkt-Leitzins-zum-sechsten-Mal-seit-Sommer-article25611145.html
These are the most important dates for the coming week:
Tuesday: 00:50 GDP figures (Japan)
Wednesday: 13:30 Inflation data (USA)
Thursday: 13:30 Producer prices (USA)
Can you think of any other dates? Write it in the comments 👇
BYD increases e-vehicle sales
BYD $1211 (-7,35%) is continuing its impressive growth trajectory and is making a good start. In February 2025, sales figures for plug-in vehicles rose by an impressive 161% compared to the previous year. The company sold a total of 322,846 vehicles, which shows a clear upward trend. Particularly exciting is the massive increase in pure electric vehicles, where sales figures rose by 127.5 percent and 124,902 BEVs were sold. However, plug-in hybrids remain the dominant vehicle category with 193,331 units sold. Investors are delighted with these strong figures: BYD shares rose by 5.79 percent to 51.15 Hong Kong dollars, raising hopes for a continued successful future.
Freenet plans dividend increase
Freenet $FNTN (-5,99%) achieved its targets last year and is now planning a dividend increase, which will put shareholders in a good mood. EBITDA climbed by 3.5 percent to 521.5 million euros, supported by a special effect from the sale of IP addresses. Free cash flow was also strong and improved to 292.3 million euros. Revenues grew by 3.9% to EUR 2.478 billion, with growth being driven primarily by waipu.tv subscription customers. The dividend is to be increased to EUR 1.97 per share. The Management Board is also planning a share buyback program with a volume of up to EUR 100 million, underlining its confidence in the company's future development.
Bayer expects profit decline
Bayer $BAYN (-6,12%) expects a further decline in operating profit in 2025, particularly in the agricultural business. The company faces continued headwinds that could have a negative impact on business results. While the exact figures and forecasts are still to come, there are already early indications that market conditions will remain challenging. It remains to be seen how this development will affect the stock and whether Bayer will be able to withstand the market challenges.
Sources:
The euro has been weakening since September 2024 and is approaching parity with the dollar - the currency ratio would then be one to one. The dollar is currently still worth around 1.04 euros, up seven cents in the fall.
German companies with strong business in the dollar area can benefit from this development in several ways.
"The strength of the dollar is good news for exporting German companies," comment the analysts at Baader Bank. This is because their products are comparatively cheaper in the USA.
A weak euro makes exports cheaper, making European products and services cheaper and more competitive in the dollar area and thus in large parts of America and Asia. Import duties in the USA would make products more expensive again - but in the end, the two effects could almost balance each other out.
For example, the medical technology group Siemens Healthineers $SHL (-5,55%) is hardly worried about the threat of import duties in the USA. The company shares the fear of a global trade war. However, the company expects that the headwind from tariffs and the tailwind from the stronger dollar will largely balance each other out, says CFO Jochen Schmitz.
The tailwind from the strong dollar could remain with companies for a long time to come. "The euro will become a really weak currency. It should quickly fall below parity with the dollar and be at 0.95 euros per dollar quite quickly," expects the well-known fund manager Jens Ehrhardt, founder and CEO of DJE Kapital.
The European Central Bank (ECB) expects the strength of the dollar to ease the burden on exporting companies in the event of possible import tariffs in the USA. ECB Governing Council member Pierre Wunsch says: "The euro would have to be brought to parity in order to essentially compensate for a tariff of ten percent."
The many companies that produce locally in the USA and sell their goods there also benefit from a strong dollar. This is because the effect on the balance sheet is even stronger as soon as companies convert their earnings generated in the dollar zone into their home currency. For every dollar earned, there are currently seven euro cents more than in the fall.
Companies are already feeling the effects. For example, Infineon $IFX (-8,33%) raised its forecast for the current financial year a few days ago. Previously, the Munich-based semiconductor manufacturer had assumed a slight decline in turnover. The DAX-listed company now expects stable to slightly increasing revenue in 2024.
One reason is the strength of the dollar. Infineon is now assuming a euro-dollar exchange rate of 1.05 euros this year - after previously assuming 1.10 euros. "This adjustment and the better exchange rate in the first quarter increase our revenue expectations by around 450 million euros," calculates Group CEO Jochen Hanebeck.
The estimates show: The biggest currency beneficiaries of a weaker euro are highly globalized companies with strong business in the dollar area. In addition to Infineon, these include $BAYN (-6,12%) Bayer with its strong US business and the DAX heavyweight Airbus $AIR (-8,31%). The European joint venture mainly builds aircraft in Germany and France, but they are sold worldwide at dollar prices.
Rheinmetall $RHM (-10,98%) also benefits: Armaments are usually invoiced in dollars, but the Düsseldorf-based group reports them in euros, which results in higher revenues from the conversion alone.
There are also profiteers in the financial sector. Deutsche Bank $DBK (-10%) CFO James von Moltke hinted at the outlook for 2025: There is potential for higher Group revenues than the 32 billion euros targeted so far, he said. So far, the bank has been planning with an exchange rate of 1.10 dollars per euro - i.e. a euro that is more than five cents stronger than it is currently worth. However, as Deutsche Bank has more income in dollars than costs in dollars and does not hedge this currency risk, it benefits from a weak euro, according to Moltke.
The weak euro also helps the automotive industry. Many luxury vehicles are produced in Germany, but sold worldwide, especially in the USA. Porsche $P911 (-4,36%) sells every fourth car there - but does not produce a single one.
"This will have a positive impact of several hundred million euros on Porsche's balance sheet," says a Frankfurt stock trader with a view to this year's results. However, US tariffs on imports of European cars could offset this positive effect.
Source & graphic: Handelsblatt
January 20-24, 2025, Davos, Switzerland
The World Economic Forum (WEF) is an international organization founded by Klaus Schwab in Switzerland in 1971. It promotes cooperation between business, politics, science & civil society. The Annual Meeting takes place in Davos. The motto for this year:
"Cooperation in the age of intelligence"
The World Economic Forum 2025 is dedicated to a wide range of topics, including geopolitical tensions, economic growth and the transition to clean energy. At the same time, tech, AI, quantum computing & biotech also play an important role.
As always, there will be posts on all relevant topics from @HennRes & @Michael-official will be published. Under the #wef2025 you will be able to view all posts in chronological order.
Main topics:
Participants from politics & business.
Over 350 government representatives, including 60 heads of state & government, 1600 people from the private sector, including 900 CEOs and over 170 people from NGOs, trade unions, academia and indigenous peoples are also present.
The key figures from politics are:
Executives from the private sector (who are expected/ not offical)
Technology sector
Financial sector
Banking sector
Industry sector
... and many more from the Tech, Banking, AI, Biotech, Pharma, Industrial, etc. sectors.